Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22356126 | 0.88 | — | — | |
| SCHEMBL2239226 | 0.88 | — | — | |
| SCHEMBL19558723 | 0.88 | — | — | |
| SCHEMBL4691011 | 0.82 | EPHX1 (0.34) | EPHX1GRM5ACACBNAAA | |
| SCHEMBL18319305 | 0.80 | GRM5 (0.34) | EPHX1GRM5ACACBNAAA | |
| SCHEMBL4539270 | 0.80 | ACACB (0.36) | EPHX1GRM5ACACBNAAA | |
| SCHEMBL16782377 | 0.80 | ACACB (0.36) | EPHX1GRM5ACACBNAAA | |
| SCHEMBL8196802 | 0.80 | EPHX1 (0.33) | EPHX1GRM5ACACBJAK2JAK1 | |
| SCHEMBL28360817 | 0.78 | CHRM2 (0.33) | EPHX1GRM5ACACB | |
| SCHEMBL13829862 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689664-B | Tricyclic heteroaryl substituted quinoline and azaquinoline compounds as PAR4 inhibitors | 百时美施贵宝公司 | 2022-04-15 | — | — | CN | claimed |
| US-12312362-B2 | Spiro derivatives of Alpha-D-galactopyranosides | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-05-27 | — | — | US | disclosed |
| US-20230295182-A1 | SPIRO DERIVATIVES OF ALPHA-D-GALACTOPYRANOSIDES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-09-21 | — | — | US | disclosed |
| CN-109689664-B | Tricyclic heteroaryl substituted quinoline and azaquinoline compounds as PAR4 inhibitors | 百时美施贵宝公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-2094081-A1 | TRICYCLIC HETEROAROMATIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008060488-A1 | TRICYCLIC HETEROAROMATIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312362-B2 | Spiro derivatives of Alpha-D-galactopyranosides | LGALS1, LGALS3, LGALS2 | ATM 3792/4885EPHX1 4305/4885GRM5 2832/4885 |
| US-20230295182-A1 | SPIRO DERIVATIVES OF ALPHA-D-GALACTOPYRANOSIDES | LGALS1, LGALS3, LGALS2 | ATM 3792/4885EPHX1 4305/4885GRM5 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.